High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial

<p>Abstract</p> <p>Background</p> <p>The use of Lamivudine in chronic hepatitis B (CHB) is well known, however the reported rate of HBeAg sero-conversion and its durability post-treatment have varied considerably. We undertook the present study to study the effect of La...

Full description

Bibliographic Details
Main Authors: Negi TS, Chetri Kamal, Baba Chalamalasetty S, Alexander George, Choudhuri Gourdas
Format: Article
Language:English
Published: BMC 2005-09-01
Series:BMC Gastroenterology
Online Access:http://www.biomedcentral.com/1471-230X/5/29
id doaj-e88c6edc42694da99fbe44039d28cdea
record_format Article
spelling doaj-e88c6edc42694da99fbe44039d28cdea2020-11-25T01:43:56ZengBMCBMC Gastroenterology1471-230X2005-09-01512910.1186/1471-230X-5-29High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trialNegi TSChetri KamalBaba Chalamalasetty SAlexander GeorgeChoudhuri Gourdas<p>Abstract</p> <p>Background</p> <p>The use of Lamivudine in chronic hepatitis B (CHB) is well known, however the reported rate of HBeAg sero-conversion and its durability post-treatment have varied considerably. We undertook the present study to study the effect of Lamivudine on HBeAg loss and seroconversion rates in Indian patients of CHB in relation to frequency, predictors and durability.</p> <p>Methods</p> <p>We treated 60 patients of e antigen positive CHB (with active viral replication and ongoing necro-inflammatory activity) with Lamivudine. They were followed up by monthly aminotransferases, and 3 monthly HBeAg and anti-HBe. Those who attained HBeAg sero-conversion were advised to discontinue Lamivudine after 6 months and followed up every 3 months thereafter, to see for relapse. Treatment was given for maximum of 3 years if not sero-converted.</p> <p>Results</p> <p>The annual incremental loss of HBeAg in patients receiving Lamivudine was 25 (41.6%) at end of 1<sup>st </sup>year, 33 (55%) at 2<sup>nd </sup>year and 35 (58.3%) at 3<sup>rd </sup>year. The corresponding rates for full sero-conversion were 17/60 (28.6%), 22/60 (36.6%) and 24/60 (40%) in the 3 years. HBeAg loss correlated with increased pre-therapy ALT levels (p = 0.002) and decreased pretreatment HBV-DNA levels (p = 0.004). The presence of cirrhosis had no influence on the rate of HBeAg loss. Relapse occurred in 35% (7/20) post-treatment at median time of 6 months.</p> <p>Conclusion</p> <p>Indian patients showed a higher rate of HBeAg sero-conversion in the first year of Lamivudine treatment. This correlated with baseline ALT and inversely with HBV-DNA levels. Relapse rate after treatment was high and occurred soon after stopping treatment.</p> http://www.biomedcentral.com/1471-230X/5/29
collection DOAJ
language English
format Article
sources DOAJ
author Negi TS
Chetri Kamal
Baba Chalamalasetty S
Alexander George
Choudhuri Gourdas
spellingShingle Negi TS
Chetri Kamal
Baba Chalamalasetty S
Alexander George
Choudhuri Gourdas
High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial
BMC Gastroenterology
author_facet Negi TS
Chetri Kamal
Baba Chalamalasetty S
Alexander George
Choudhuri Gourdas
author_sort Negi TS
title High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial
title_short High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial
title_full High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial
title_fullStr High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial
title_full_unstemmed High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial
title_sort high rates of early hbeag seroconversion and relapse in indian patients of chronic hepatitis b treated with lamivudine: results of an open labeled trial
publisher BMC
series BMC Gastroenterology
issn 1471-230X
publishDate 2005-09-01
description <p>Abstract</p> <p>Background</p> <p>The use of Lamivudine in chronic hepatitis B (CHB) is well known, however the reported rate of HBeAg sero-conversion and its durability post-treatment have varied considerably. We undertook the present study to study the effect of Lamivudine on HBeAg loss and seroconversion rates in Indian patients of CHB in relation to frequency, predictors and durability.</p> <p>Methods</p> <p>We treated 60 patients of e antigen positive CHB (with active viral replication and ongoing necro-inflammatory activity) with Lamivudine. They were followed up by monthly aminotransferases, and 3 monthly HBeAg and anti-HBe. Those who attained HBeAg sero-conversion were advised to discontinue Lamivudine after 6 months and followed up every 3 months thereafter, to see for relapse. Treatment was given for maximum of 3 years if not sero-converted.</p> <p>Results</p> <p>The annual incremental loss of HBeAg in patients receiving Lamivudine was 25 (41.6%) at end of 1<sup>st </sup>year, 33 (55%) at 2<sup>nd </sup>year and 35 (58.3%) at 3<sup>rd </sup>year. The corresponding rates for full sero-conversion were 17/60 (28.6%), 22/60 (36.6%) and 24/60 (40%) in the 3 years. HBeAg loss correlated with increased pre-therapy ALT levels (p = 0.002) and decreased pretreatment HBV-DNA levels (p = 0.004). The presence of cirrhosis had no influence on the rate of HBeAg loss. Relapse occurred in 35% (7/20) post-treatment at median time of 6 months.</p> <p>Conclusion</p> <p>Indian patients showed a higher rate of HBeAg sero-conversion in the first year of Lamivudine treatment. This correlated with baseline ALT and inversely with HBV-DNA levels. Relapse rate after treatment was high and occurred soon after stopping treatment.</p>
url http://www.biomedcentral.com/1471-230X/5/29
work_keys_str_mv AT negits highratesofearlyhbeagseroconversionandrelapseinindianpatientsofchronichepatitisbtreatedwithlamivudineresultsofanopenlabeledtrial
AT chetrikamal highratesofearlyhbeagseroconversionandrelapseinindianpatientsofchronichepatitisbtreatedwithlamivudineresultsofanopenlabeledtrial
AT babachalamalasettys highratesofearlyhbeagseroconversionandrelapseinindianpatientsofchronichepatitisbtreatedwithlamivudineresultsofanopenlabeledtrial
AT alexandergeorge highratesofearlyhbeagseroconversionandrelapseinindianpatientsofchronichepatitisbtreatedwithlamivudineresultsofanopenlabeledtrial
AT choudhurigourdas highratesofearlyhbeagseroconversionandrelapseinindianpatientsofchronichepatitisbtreatedwithlamivudineresultsofanopenlabeledtrial
_version_ 1725030744299929600